Joshi V V, Chatten J, Sather H N, Shimada H
Children's Hospital of New Jersey, Newark.
Mod Pathol. 1991 Mar;4(2):139-47.
Histopathology of 46 cases of Stage III and Stage IV neuroblastoma collected at the Childrens Cancer Study Group Pathology Center was reviewed independently by two pathologists to formulate essential steps in the determination of the mitosis-karyorrhexis index (MKI), to assess interobserver concordance, and to evaluate prognostic significance of the Shimada classification system. "Absolute" agreement (obtained after the review by both pathologists) or "consensus" agreement (obtained after the second review of cases with initial discrepancy) was achieved with respect to category of MKI in 93% of 40 stroma-poor neuroblastomas and prognostic subgrouping in 98% of the total cases. This classification system distinguished favorable from unfavorable prognostic subgroups significantly (P = 0.0002), and the prognostic effects were largely unaltered when adjusted for age and stage of the patients (P = 0.0005) in this series.
儿童癌症研究组病理中心收集的46例III期和IV期神经母细胞瘤的组织病理学由两名病理学家独立审查，以制定确定有丝分裂-核溶解指数（MKI）的基本步骤，评估观察者间的一致性，并评估岛田分类系统的预后意义。在40例低基质神经母细胞瘤中，93%的病例在MKI类别方面达成了“绝对”一致（经过两名病理学家审查后获得）或“共识”一致（在对最初存在差异的病例进行二次审查后获得），在所有病例中，98%的病例在预后亚组分类方面达成了一致。该分类系统显著区分了预后良好和不良的亚组（P = 0.0002），在本系列中，对患者的年龄和分期进行调整后，预后效果基本未改变（P = 0.0005）。
